Quarterly report pursuant to Section 13 or 15(d)

Segment, Geographical and Other Revenue Information - Segment Reporting (Details)

v3.19.3
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Segment Reporting Information [Line Items]        
Total revenues $ 21,906 $ 16,946 $ 49,808 $ 44,526
Cost of product revenue 5,067 3,791 12,230 10,228
Research and development 8,711 7,917 25,000 22,464
Selling, general and administrative 7,869 7,344 24,180 22,485
Total costs and operating expenses 21,647 19,052 61,410 55,177
Income (loss) from operations 259 (2,106) (11,602) (10,651)
Depreciation and amortization     (1,118) (812)
Income (loss) before income taxes 336 (1,987) (11,288) (10,428)
Stock-based compensation 1,732 1,770 5,783 6,207
Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 20,424 12,125 41,100 34,019
Novel Biotherapeutics [Member]        
Segment Reporting Information [Line Items]        
Total revenues 1,482 4,821 8,708 10,507
Operating Segments [Member]        
Segment Reporting Information [Line Items]        
Total revenues 21,906 16,946 49,808 44,526
Cost of product revenue 5,067 3,791 12,230 10,228
Research and development 8,393 7,678 24,141 21,842
Selling, general and administrative 2,727 2,035 8,267 6,310
Total costs and operating expenses 16,187 13,504 44,638 38,380
Income (loss) from operations 5,719 3,442 5,170 6,146
Stock-based compensation 961 451 2,536 2,248
Operating Segments [Member] | Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 20,424 12,125 41,100 34,019
Cost of product revenue 5,067 3,791 12,230 10,228
Research and development 5,313 4,758 14,889 14,548
Selling, general and administrative 2,037 1,870 6,499 5,695
Total costs and operating expenses 12,417 10,419 33,618 30,471
Income (loss) from operations 8,007 1,706 7,482 3,548
Stock-based compensation 736 354 1,973 2,005
Operating Segments [Member] | Novel Biotherapeutics [Member]        
Segment Reporting Information [Line Items]        
Total revenues 1,482 4,821 8,708 10,507
Research and development 3,080 2,920 9,252 7,294
Selling, general and administrative 690 165 1,768 615
Total costs and operating expenses 3,770 3,085 11,020 7,909
Income (loss) from operations (2,288) 1,736 (2,312) 2,598
Stock-based compensation 225 97 563 243
Corporate [Member]        
Segment Reporting Information [Line Items]        
Total costs and operating expenses 4,912 5,120 15,185 15,762
Depreciation and amortization (471) (309) (1,273) (812)
Product Sales [Member]        
Segment Reporting Information [Line Items]        
Total revenues 10,351 8,405 24,588 18,291
Product Sales [Member] | Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 10,351 8,405 24,588 18,291
Product Sales [Member] | Operating Segments [Member]        
Segment Reporting Information [Line Items]        
Total revenues 10,351 8,405 24,588 18,291
Product Sales [Member] | Operating Segments [Member] | Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 10,351 8,405 24,588 18,291
Research and Development Revenue [Member]        
Segment Reporting Information [Line Items]        
Total revenues 11,555 8,541 25,220 26,235
Research and Development Revenue [Member] | Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 10,073 3,720 16,512 15,728
Research and Development Revenue [Member] | Novel Biotherapeutics [Member]        
Segment Reporting Information [Line Items]        
Total revenues 1,482 4,821 8,708 10,507
Research and Development Revenue [Member] | Operating Segments [Member]        
Segment Reporting Information [Line Items]        
Total revenues 11,555 8,541 25,220 26,235
Research and Development Revenue [Member] | Operating Segments [Member] | Performance Enzymes [Member]        
Segment Reporting Information [Line Items]        
Total revenues 10,073 3,720 16,512 15,728
Research and Development Revenue [Member] | Operating Segments [Member] | Novel Biotherapeutics [Member]        
Segment Reporting Information [Line Items]        
Total revenues $ 1,482 $ 4,821 $ 8,708 $ 10,507